Because mutant KRAS cancers are largely refractory to therapy14, our data show that the adaptive role of ISR in the addiction of tumors to KRAS mutations is a rational target for the implementation of effective therapies against a deadly form of lung cancer. Here, KRAS is linked to lung cancer.